Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK1 | P49759 | 6/20 | 0.40 |
| ▸ | LIMK1 | P53667 | 3/20 | 0.40 |
| ▸ | CDC7 | O00311 | 1/20 | 0.40 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 3/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | PRKCI | P41743 | 3/20 | 0.33 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.33 |
| ▸ | TLR5 | O60602 | 1/20 | 0.32 |
| ▸ | IKBKB | O14920 | 1/20 | 0.32 |
| ▸ | CHUK | O15111 | 1/20 | 0.32 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26423734 | 0.81 | CLK1 (0.40) | CLK1LIMK1CDC7DBF4PIK3CA | |
| SCHEMBL26423746 | 0.80 | LIMK1 (0.40) | CLK1LIMK1PIK3CAEGFRKDM4E | |
| SCHEMBL26423730 | 0.80 | LIMK1 (0.36) | CLK1LIMK1CDC7DBF4PIK3CA | |
| SCHEMBL26423725 | 0.78 | KDM4E (0.36) | CLK1LIMK1EGFRKDM4ELMNA | |
| SCHEMBL2855389 | 0.77 | CLK1 (0.51) | CLK1LIMK1CDC7DBF4PIK3CA | |
| SCHEMBL26423747 | 0.77 | LATS1 (0.33) | CLK1LIMK1EGFRKDM4ECYP2A6 | |
| SCHEMBL26423745 | 0.77 | EGFR (0.33) | EGFRCYP2A6 | |
| SCHEMBL26423577 | 0.77 | LIMK1 (0.41) | CLK1LIMK1CDC7DBF4PIK3CA | |
| SCHEMBL26423677 | 0.76 | EGFR (0.38) | CLK1LIMK1CDC7DBF4PIK3CA | |
| SCHEMBL26423708 | 0.75 | LIMK1 (0.40) | CLK1LIMK1CDC7DBF4PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230127291-A1 | HETEROCYCLIC ARYLAMINE COMPOUND, ORGANIC ELECTROLUMINESCENT DEVICE AND DISPLAY PANEL | WUHAN TIANMA MICROELECTRONICS CO., LTD. (CN) | 2023-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230127291-A1 | HETEROCYCLIC ARYLAMINE COMPOUND, ORGANIC ELECTROLUMINESCENT DEVICE AND DISPLAY PANEL | OCIAD2, OCIAD1, AZI2 | CLK1 4489/4885LIMK1 1525/4885CDC7 1258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.